(MYGN) Myriad Genetics - Overview
Oncology Tests, Womens Health, Pharmacogenomics, Prenatal Screens
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.9% |
| Relative Tail Risk | -13.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.48 |
| Alpha | -76.94 |
| Character TTM | |
|---|---|
| Beta | 1.278 |
| Beta Downside | 1.086 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.57% |
| CAGR/Max DD | -0.40 |
Description: MYGN Myriad Genetics December 27, 2025
Myriad Genetics (NASDAQ:MYGN) is a U.S. molecular diagnostics firm that commercializes DNA- and RNA-based tests across oncology, women’s health, pharmacogenomics, and mental-health domains. Its flagship offerings include MyRisk (hereditary cancer risk), BRACAnalysis CDx (germline BRCA companion diagnostic), MyChoice CDx (homologous recombination deficiency in ovarian cancer), Prolaris (prostate cancer aggressiveness), EndoPredict (breast cancer aggressiveness), Precise Tumor Molecular Profile (comprehensive genomic profiling), and a suite of prenatal screens (Prequel, Foresight, SneakPeek). The company partners with Illumina, major cancer centers (MSKCC, MD Anderson, Rochester), Flatiron Health, and SOPHiA GENETICS for liquid-biopsy development.
Key recent metrics: FY 2023 revenue reached approximately $1.0 billion, up ~4 % year-over-year, while cash and short-term investments stood at $1.2 billion, providing ample runway for R&D and potential acquisitions. Test volume grew ~8 % YoY, driven by expanding reimbursement for companion diagnostics and increasing adoption of precision-medicine protocols in oncology. A sector-wide driver is the aging U.S. population, which is expected to lift demand for cancer-related molecular testing at a CAGR of roughly 7 % through 2030.
For a deeper quantitative assessment, you might explore ValueRay’s analyst notes on MYGN.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -400.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 6.34 > 1.0 |
| NWC/Revenue: 23.85% < 20% (prev 16.86%; Δ 6.98% < -1%) |
| CFO/TA -0.00 > 3% & CFO -2.20m > Net Income -400.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.1m) vs 12m ago 2.42% < -2% |
| Gross Margin: 70.36% > 18% (prev 0.69%; Δ 6967 % > 0.5%) |
| Asset Turnover: 91.22% > 50% (prev 76.17%; Δ 15.06% > 0%) |
| Interest Coverage Ratio: -61.54 > 6 (EBITDA TTM -362.6m / Interest Expense TTM 6.80m) |
Altman Z'' -9.62
| A: 0.27 (Total Current Assets 344.8m - Total Current Liabilities 148.0m) / Total Assets 728.1m |
| B: -1.53 (Retained Earnings -1.11b / Total Assets 728.1m) |
| C: -0.46 (EBIT TTM -418.5m / Avg Total Assets 904.7m) |
| D: -3.14 (Book Value of Equity -1.11b / Total Liabilities 355.3m) |
| Altman-Z'' Score: -9.62 = D |
Beneish M -3.93
| DSRI: 0.94 (Receivables 118.0m/125.7m, Revenue 825.3m/823.6m) |
| GMI: 0.98 (GM 70.36% / 69.15%) |
| AQI: 0.53 (AQ_t 0.30 / AQ_t-1 0.57) |
| SGI: 1.00 (Revenue 825.3m / 823.6m) |
| TATA: -0.55 (NI -400.5m - CFO -2.20m) / TA 728.1m) |
| Beneish M-Score: -3.93 (Cap -4..+1) = AAA |
What is the price of MYGN shares?
Over the past week, the price has changed by -2.05%, over one month by -9.35%, over three months by -29.64% and over the past year by -54.24%.
Is MYGN a buy, sell or hold?
- StrongBuy: 3
- Buy: 3
- Hold: 6
- Sell: 2
- StrongSell: 1
What are the forecasts/targets for the MYGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.1 | 42% |
| Analysts Target Price | 8.1 | 42% |
| ValueRay Target Price | 4.3 | -24.7% |
MYGN Fundamental Data Overview January 29, 2026
P/S = 0.6686
P/B = 1.4802
P/EG = 1.4001
Revenue TTM = 825.3m USD
EBIT TTM = -418.5m USD
EBITDA TTM = -362.6m USD
Long Term Debt = 119.5m USD (from longTermDebt, last quarter)
Short Term Debt = 15.8m USD (from shortTermDebt, last quarter)
Debt = 212.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 66.9m USD (from netDebt column, last quarter)
Enterprise Value = 618.7m USD (551.8m + Debt 212.3m - CCE 145.4m)
Interest Coverage Ratio = -61.54 (Ebit TTM -418.5m / Interest Expense TTM 6.80m)
EV/FCF = -23.71x (Enterprise Value 618.7m / FCF TTM -26.1m)
FCF Yield = -4.22% (FCF TTM -26.1m / Enterprise Value 618.7m)
FCF Margin = -3.16% (FCF TTM -26.1m / Revenue TTM 825.3m)
Net Margin = -48.53% (Net Income TTM -400.5m / Revenue TTM 825.3m)
Gross Margin = 70.36% ((Revenue TTM 825.3m - Cost of Revenue TTM 244.6m) / Revenue TTM)
Gross Margin QoQ = 69.91% (prev 71.23%)
Tobins Q-Ratio = 0.85 (Enterprise Value 618.7m / Total Assets 728.1m)
Interest Expense / Debt = 1.79% (Interest Expense 3.80m / Debt 212.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -330.6m (EBIT -418.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.33 (Total Current Assets 344.8m / Total Current Liabilities 148.0m)
Debt / Equity = 0.57 (Debt 212.3m / totalStockholderEquity, last quarter 372.8m)
Debt / EBITDA = -0.18 (negative EBITDA) (Net Debt 66.9m / EBITDA -362.6m)
Debt / FCF = -2.56 (negative FCF - burning cash) (Net Debt 66.9m / FCF TTM -26.1m)
Total Stockholder Equity = 541.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.27% (Net Income -400.5m / Total Assets 728.1m)
RoE = -73.93% (Net Income TTM -400.5m / Total Stockholder Equity 541.7m)
RoCE = -63.29% (EBIT -418.5m / Capital Employed (Equity 541.7m + L.T.Debt 119.5m))
RoIC = -54.09% (negative operating profit) (NOPAT -330.6m / Invested Capital 611.2m)
WACC = 8.06% (E(551.8m)/V(764.1m) * Re(10.62%) + D(212.3m)/V(764.1m) * Rd(1.79%) * (1-Tc(0.21)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.99%
Fair Price DCF = unknown (Cash Flow -26.1m)
EPS Correlation: 14.25 | EPS CAGR: 2.86% | SUE: 0.12 | # QB: 0
Revenue Correlation: 88.90 | Revenue CAGR: 6.79% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.00 | Chg30d=+0.003 | Revisions Net=+2 | Analysts=11
EPS next Year (2026-12-31): EPS=0.07 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=+1636.6% | Growth Revenue=+5.5%